| Filed On | Filing |
|---|---|
| 14 Oct 2026 | PRELIMINARY INFORMATION STATEMENT |
| 14 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 13, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent: |
| 14 Oct 2026 | SCHEDULE 13G |
| 13 Oct 2026 | SCHEDULE 13G |
| 09 Oct 2026 | PROSPECTUS |
| 09 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed Best Efforts Secondary Of... |
| 07 Oct 2026 | EFFECT |
| 05 Oct 2026 | SCHEDULE 13G/A |
| 02 Oct 2026 | FORM S-1 |
| 28 Sep 2026 | DEFINITIVE INFORMATION STATEMENT |
| 24 Sep 2026 | DRS |
| 16 Sep 2026 | PRELIMINARY PROXY |
| 16 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s board of directors to ef... |
| 11 Sep 2026 |
8-K: Other Events
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. |
| 08 Sep 2026 | FORM 424B3 |
| 08 Sep 2026 | EFFECT |
| 28 Aug 2026 | FORM S-1 |
| 28 Aug 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
Loading...
